Prelude Therapeutics Beats Third-Quarter Loss Estimate of $0.14 per Share
Key Facts
Prelude Therapeutics beat Zacks’ estimate for its third-quarter 2026 loss per share, which stood at a loss of $0.14, according to a Zacks news summary. The company reported its financial results and provided a business update on November 16. Revenue fell to $5.647 million, compared with $6.500 million in the third quarter of 2025. The figures put a better-than-expected loss per share alongside a year-over-year decline in revenue. The company is developing clinical-stage therapies, while its reported liquidity provides a time frame for funding its operations and research programs.
Research and development expenses fell to $14.8 million in the third quarter from $21.7 million in the same period a year earlier. The company attributed the decline to lower spending on clinical trials for SMARCA2 therapies after it discontinued those trials in 2025. It also cited lower employee-related costs following workforce reductions in the second half of 2025. This is part of a cost-cutting trend that also appeared in the second quarter of 2026, when research and development expenses were $16.1 million, compared with $25.8 million in the second quarter of 2025. These comparisons show year-over-year declines in research spending in both quarters, with the company linking part of the decrease to earlier changes in trials and staffing.
Cash, restricted cash and marketable securities totaled $142.7 million on September 30, 2026. Prelude said it expects these resources to fund its operations through the second quarter of 2028. The estimate gives the company a stated time horizon for continuing its research and clinical activities. The programs it disclosed focus on therapies targeting specific types of cancer and blood disorders. In this context, the quarterly results combine lower revenue and research and development expenses with a cash balance the company said would cover operations through the specified period.
The company has begun enrolling patients in a Phase 1 study of PRT13722, an oral therapy targeting KAT6A, in patients with hormone receptor-positive, HER2-negative breast cancer. Prelude expects initial proof-of-concept data in the second half of 2027. In October 2026, the company entered into a clinical collaboration and supply agreement with Eli Lilly to evaluate PRT13722 in combination with abemaciclib and imlunestrant in the ongoing Phase 1 study. It also said the Phase 1 study of PRT12396, a selective inhibitor of JAK2V617F mutations, continues to enroll patients with polycythemia vera and myelofibrosis. These developments tie the company’s expectations for upcoming data to the progress of clinical studies that remain in their early stages.
Among the upcoming events it announced, the company will participate in a fireside chat at the Evercore Healthcare Conference on December 2, 2026. Prelude scheduled the chat for 7:55 a.m. U.S. Eastern time. The event follows the release of its third-quarter results and update on its clinical programs and liquidity. The company’s stock closed at $3.45 on November 13, according to EL7 data. The earnings announcement did not comment on the stock’s close in that session.